S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:GRFS

Grifols (GRFS) Stock Forecast, Price & News

$12.96
+0.44 (+3.51%)
(As of 05/13/2022 06:55 PM ET)
Add
Compare
Today's Range
$12.61
$13.00
50-Day Range
$10.37
$12.96
52-Week Range
$10.10
$19.07
Volume
664,200 shs
Average Volume
993,717 shs
Market Capitalization
$8.79 billion
P/E Ratio
11.37
Dividend Yield
2.78%
Beta
0.43
30 days | 90 days | 365 days | Advanced Chart
Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

Grifols logo

About Grifols

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum-from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring-to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Headlines

Grifols: Long Only - Seeking Alpha
Form 20-F Grifols SA For: Dec 31 - StreetInsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRFS
Employees
23,234
Year Founded
1909

Sales & Book Value

Annual Sales
$5.84 billion
Cash Flow
$1.07 per share
Book Value
$12.76 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$8.79 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2021
Today
5/16/2022
Next Earnings (Estimated)
5/17/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.19 out of 5 stars

Medical Sector

513th out of 1,403 stocks

Pharmaceutical Preparations Industry

228th out of 667 stocks

Analyst Opinion: 2.1Community Rank: 3.9Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -













Grifols (NASDAQ:GRFS) Frequently Asked Questions

Is Grifols a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Grifols stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRFS, but not buy additional shares or sell existing shares.
View analyst ratings for Grifols
or view top-rated stocks.

When is Grifols' next earnings date?

Grifols is scheduled to release its next quarterly earnings announcement on Tuesday, May 17th 2022.
View our earnings forecast for Grifols
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) announced its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 EPS for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter.
View Grifols' earnings history
.

How often does Grifols pay dividends? What is the dividend yield for Grifols?

Grifols announced a semi-annual dividend on Wednesday, May 26th. Investors of record on Friday, June 4th will be given a dividend of $0.4385 per share on Monday, June 14th. This represents a dividend yield of 2.6%. The ex-dividend date is Thursday, June 3rd. This is a positive change from Grifols's previous semi-annual dividend of $0.14.
View Grifols' dividend history
.

Is Grifols a good dividend stock?

Grifols pays an annual dividend of $0.36 per share and currently has a dividend yield of 2.78%. The dividend payout ratio of Grifols is 31.58%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Grifols will have a dividend payout ratio of 27.07% next year. This indicates that Grifols will be able to sustain or increase its dividend.
View Grifols' dividend history.

When did Grifols' stock split? How did Grifols' stock split work?

Shares of Grifols split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were issued to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols stock prior to the split would have 200 shares after the split.

What price target have analysts set for GRFS?

5 brokers have issued 12 month price targets for Grifols' shares. Their forecasts range from $11.00 to $21.40. On average, they expect Grifols' stock price to reach $16.20 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts' price targets for Grifols
or view top-rated stocks among Wall Street analysts.

Who are Grifols' key executives?
Grifols' management team includes the following people:
  • Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 58, Pay $950.59k)
  • Mr. Víctor Grifols Deu, Co-CEO & Exec. Director (Age 45, Pay $950.59k)
  • Mr. Alfredo Arroyo Guerra, CFO & VP (Age 64)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs
  • Ms. Nuria Pascual Lapeña, VP of Corp. Treasury & Investor Relations (Age 58)
  • Mr. David Ian Bell, Gen. Counsel & Chief Corp. Devel. Officer (Age 67)
  • Ms. Maria Teresa-Rioné Llano, VP of Corp. Communications (Age 56)
  • Mr. Mateo Florencio Borrás Humbert, Corp. VP & Chief HR Officer (Age 66)
  • Mr. Francisco Javier Jorba Ribes, Corp. VP and Pres of the Biological Industrial Group (Age 71)
  • Mrs. Montserrat Lloveras Calvo, Corp. VP and Director of Corp. Accounting & Reporting (Age 60)
What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols CEO Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among Grifols' employees.

What other stocks do shareholders of Grifols own?
What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Who are Grifols' major shareholders?

Grifols' stock is owned by many different institutional and retail investors. Top institutional shareholders include Black Creek Investment Management Inc. (1.04%), Brandes Investment Partners LP (0.72%), First Trust Advisors LP (0.58%), JPMorgan Chase & Co. (0.47%), BlackRock Inc. (0.37%) and Arrowstreet Capital Limited Partnership (0.24%).

Which major investors are selling Grifols stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Citigroup Inc., First Trust Advisors LP, Qube Research & Technologies Ltd, JPMorgan Chase & Co., South Dakota Investment Council, Bank of Montreal Can, and GABELLI & Co INVESTMENT ADVISERS INC..

Which major investors are buying Grifols stock?

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Black Creek Investment Management Inc., Brandes Investment Partners LP, BlackRock Inc., SG Americas Securities LLC, New York State Common Retirement Fund, Sivik Global Healthcare LLC, Natixis Advisors L.P., and Sei Investments Co..

How do I buy shares of Grifols?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $12.96.

How much money does Grifols make?

Grifols has a market capitalization of $8.79 billion and generates $5.84 billion in revenue each year. The biotechnology company earns $223.28 million in net income (profit) each year or $1.139990 on an earnings per share basis.

How many employees does Grifols have?

Grifols employs 23,234 workers across the globe.

Does Grifols have any subsidiaries?

The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..

When was Grifols founded?

Grifols was founded in 1909.

What is Grifols' official website?

The official website for Grifols is www.grifols.com.

How can I contact Grifols?

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at (493) 571-2200, via email at [email protected], or via fax at 34-93-571-0267.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.